Stimulating hypocretin receptors improves sleepiness and vigilance in idiopathic hypersomnia: lessons from a proof of concept study

Affiliations

Editorial

Isabelle Arnulf et al. Sleep. 2023.

. 2023 Sep 8;46(9):zsad085.

doi: 10.1093/sleep/zsad085.

¹ National Reference Center for Narcolepsy and Rare Hypersomnias, Sleep Clinic, Pitie-Salpetriere Hospital, APHP-Sorbonne University, Paris, France.

No abstract available

Comment on

Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.
Mignot E, Bogan RK, Emsellem H, Foldvary-Schaefer N, Naylor M, Neuwirth R, Faessel H, Swick T, Olsson T. Mignot E, et al. Sleep. 2023 Sep 8;46(9):zsad049. doi: 10.1093/sleep/zsad049. Sleep. 2023. PMID: 36883238 Free PMC article. Clinical Trial.

1. Mignot E, Bogan R, Emsellem H, et al. . Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia. Sleep. 2023;46(9):zsad049. doi: 10.1093/sleep/zsad049 - DOI - PMC - PubMed
1. Evans R, Kimura H, Alexander R, et al. . Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc Natl Acad Sci U S A. 2022;119:e2207531119. doi: 10.1073/pnas.2207531119 - DOI - PMC - PubMed
1. Evans R, Kimura H, Nakashima M, et al. . Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals. J Sleep Res. 2023:e13878. - PubMed
1. Dauvilliers Y, Bogan RK, Arnulf I, Scammell TE, St Louis EK, Thorpy MJ.. Clinical considerations for the diagnosis of idiopathic hypersomnia. Sleep Med Rev. 2022;66:101709. doi: 10.1016/j.smrv.2022.101709 - DOI - PubMed
1. Arnulf I, Leu-Semenescu S, Dodet P.. Precision medicine for idiopathic hypersomnia. Sleep Med Clin. 2022;17:379–398. doi: 10.1016/j.jsmc.2022.06.016 - DOI - PubMed